Alerta

Application of reagent for improving MRG15 gene expression in preparation of medicine for treating atherosclerosis

Resumen de: CN121927057A

The invention relates to application of a reagent for improving MRG15 gene expression in preparation of a medicine for treating atherosclerosis, and belongs to the technical field of biological medicine. Based on the defects that no clear molecular marker for predicting the prognosis of the atherosclerotic patient exists at present and the existing anti-atherosclerotic medicine with the main purpose of lowering lipid cannot improve the prognosis of the patient, in order to improve the treatment effect and the prognosis of the atherosclerotic patient, follow-up visit and sample dyeing are performed on the patient, so that the prognosis of the atherosclerotic patient can be A new atherosclerosis related molecule, namely MRG15, is found, correlation between improvement of MRG15 gene expression and improvement of atherosclerosis is verified, and a new prognosis target is provided for fine management of atherosclerosis patients. In order to ensure the stability of the treatment effect, a specific agonist is screened, and an excellent anti-atherosclerosis effect is achieved. Through in-vivo verification, the plaque area is reduced by 60%-70% after the small molecule medicine litamilast is applied.

Related tRF for detecting myocardial ischemia injury and detection method and application thereof

Resumen de: CN121931235A

The invention belongs to the technical field of biology, and particularly relates to related tRF for detecting myocardial ischemia injury and a detection method and application thereof. The invention provides a marker for myocardial ischemic injury, the marker is CIAtRF, and the nucleotide sequence of the CIAtRF is as shown in SEQ ID NO: 1. The expression of CIAtRF is up-regulated during myocardial injury, and CIAtRF participates in regulation and control of myocardial ischemic injury. The CIAtRF antiagomir provided by the invention can be used as an active ingredient in a product for treating myocardial ischemia reperfusion injury. By using the CIAtRF antiagomir, the expression of CIAtRF in the heart can be inhibited, the myocardial infarction area can be obviously inhibited, the fibrosis area can be reduced, and the survival rate of myocardial cells can be increased, so that myocardial ischemic injury is relieved, and the effect of improving the cardiac function is realized.

Application of SEC24D in preparation of medicine for treating atherosclerosis

Resumen de: CN121926950A

The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of SEC24D in preparation of medicines for treating atherosclerosis. The amino acid sequence of the SEC24D is as shown in SEQ ID NO.1. The medicine is a preparation which takes the SEC24D as a target spot and can inhibit the expression of the SEC24D. Clinical data and basic experiments prove that the SEC24D plays an important role in inflammation, the mRNA level of whole blood cells of the SEC24D is increased to reflect the activation of the inflammation, and we find that the mRNA level and protein level of the SEC24D are increased in the polarization process of M1 macrophages, the expression of the macrophages SEC24D is reduced, the functions of the M1 macrophages can be inhibited, and inflammatory mediators can be reduced.

Application of miR-150 inhibitor in preparation of medicine for activating adult myocardial cell reentry cell cycle

Resumen de: CN121910882A

The invention provides an application of a miR-150 inhibitor in preparation of a medicine for activating an adult myocardial cell reentry cell cycle. The invention further provides a myocardial patch, the myocardial patch contains the miR-150 inhibitor, and the miR-150 inhibitor is wrapped in intracellular delivery carriers such as lipidosome, exosome, a polymer complex and inorganic nanoparticles and is further loaded on a biodegradable hydrophilic flexible polymer film or a hydrogel material. The myocardial patch provided by the invention has good biocompatibility and biodegradability, and can be degraded and absorbed; no extra adhesive is needed, the film patch can be tightly attached to the surface of the heart by means of liquid bridge force by absorbing body fluid on the surface of the heart, and the hydrogel patch can be tightly attached to the surface of the heart by means of in-situ crosslinking on the surface of the heart to form gel. The miR-150 inhibitor can be delivered into myocardial cells to activate the proliferation potential of the myocardial cells so as to promote the proliferation of the myocardial cells of damaged myocardial tissues.

COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CARDIOMYOPATHY AND HEART FAILURE

Resumen de: WO2026085046A1

Disclosed herein is a method for detecting cardiomyopathy and heart failure in a subject, the method involving assaying a sample from the subject for decrease in gene or protein expression of a Obg Like ATPase 1 (OLA1) and/or the presence of a Y254C mutation in OLA1, thereby detecting cardiomyopathy and heart failure in the subject. Also disclosed is a method for treating cardiomyopathy, heart failure, myocardial infarction or heart attack, ischemic heart disease, coronary heart disease and hypertrophic cardiomyopathy in a subject, the method involving administering to the subject an expression vector comprising a nucleic acid sequence encoding wild-type Obg Like ATPase 1 (OLA1) operably linked to an expression control sequence.

Application of SH3RF2 in preparation of medicine for preventing or treating cardiac hypertrophy

Resumen de: CN121891513A

The invention discloses application of SH3RF2 in preparation of a medicine for preventing or treating cardiac hypertrophy, and relates to the technical field of new application of medicines. By constructing an in-vitro myocardial cell hypertrophy model and adopting gene knockout and overexpression technologies, the inventor finds that SH3RF2 gene knockout can significantly promote pressure load induced cardiac function deterioration and aggravate myocardial cell hypertrophy and cardiac fibrosis, and the SH3RF2 plays a role in inhibiting pathological myocardial hypertrophy. The SH3RF2 is applied to prevention and treatment of pathological cardiac hypertrophy, a new source is provided for preparation of the medicine for treating the cardiac hypertrophy, and meanwhile the medicinal value of the SH3RF2 is explored.

NALCN CORRELATION BETWEEN SODIUM LEAK CHANNEL NALCN AND HYPERTENSION AND COMPOSITION FOR DIAGNOSING OR TREATING HYPERTENSION USING THE SAME

Resumen de: KR20260052271A

본 발명은 나트륨 누출 통로인 NALCN 및 고혈압의 상관관계 및 이를 이용한 고혈압 진단 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 NALCN 억제제를 포함하는 고혈압 또는 혈관 합병증의 예방 또는 치료용 약학적 조성물, 또는 NALCN를 포함하는 고혈압 진단용 바이오마커 조성물에 관한 것이다. 본 발명에서는 혈관평활근에서 NALCN 채널을 통한 Na 유입 및 이를 통한 혈관수축 증가가 고혈압을 유발하는 것으로 확인하였으며, 알도스테론이 NALCN 채널 단백질 발현 증가를 통해 직접적으로 혈압을 증가시킴을 확인하였다. 또한, NALCN 채널이 혈관 긴장도와 혈압 조절에도 중요함을 확인하였으므로, 이를 이용하여 고혈압 진단 및 고혈압 치료 등 다양한 분야에 활용할 수 있다.

Application of Zdhhc1 gene in preparation of product for regulating and controlling atherosclerosis

Resumen de: CN121874183A

The invention belongs to the technical field of atherosclerosis, and particularly relates to application of a Zdhhc1 gene in preparation of a product for regulating and controlling atherosclerosis, a Zdhhc1-/-mouse is successfully constructed through a CRISPR/Cas9 technology, and an ApoE-/-/Zdhhc1-/-mouse is obtained through a method of hybridization and then selfing; it is verified that knockout of the Zdhhc1 gene under the background of ApoE deletion can affect related indexes of atherosclerosis formed by high-fat feed feeding, the protein molecule Zdhhc1 affecting the atherosclerosis process is determined for the first time, and it is verified for the first time that Zdhhc1 plays an important role in occurrence and development of atherosclerosis.

Application of plasma mtDNA in predicting congenital heart disease related to hyperglycemia in gestation period

Resumen de: CN121874340A

The invention discloses an application of plasma mtDNA in predicting congenital heart disease related to gestational hyperglycemia, and the application comprises the following steps: detecting the copy number of plasma mtDNA of offspring, and comparing the copy number with a preset threshold value to predict the risk that the offspring suffers from the congenital heart disease related to the gestational hyperglycemia. According to the invention, animal experiments find that plasma mtDNA level change has clear correlation with fetal congenital heart disease induced by hyperglycemia in gestation period for the first time, show good stability and consistency in the animal experiments, and can objectively reflect the heart state; therefore, the prediction method for reflecting the occurrence risk of the fetal congenital heart disease under the hyperglycemia state in the gestation period is established by taking the plasma mtDNA as the biomarker, can be applied to basic research, risk assessment and related technology development of heart dysplasia related to the hyperglycemia in the gestation period, and has relatively high practical value and popularization significance.

Gene combination for detecting hemangioma and vascular malformation as well as detection kit and application thereof

Resumen de: CN121852534A

The invention provides a gene detection kit for molecular diagnosis of hemangioma and vascular malformation and application. Specifically, the invention provides a gene combination for determining molecular diagnosis of hemangioma and vascular malformation, and based on NGS panel + RNAseq gene sequencing, the gene combination for molecular diagnosis of hemangioma and vascular malformation provided by the invention can be applied to all molecular diagnosis and liquid biopsy related to hemangioma and vascular malformation. The correlation between mutation sites and abundance and disease phenotypes is disclosed, so that the method has a relatively great clinical popularization and application prospect.

Biomarker combination for auxiliary diagnosis of lung adenocarcinoma and risk early warning of lung adenocarcinoma complicated with ischemic stroke and application of biomarker combination

Resumen de: CN121852541A

The invention discloses a biomarker combination for auxiliary diagnosis of lung adenocarcinoma and risk early warning of lung adenocarcinoma complicated with ischemic stroke and application of the biomarker combination. The biomarker combination comprises an SLC25A39 gene, an NME4 gene, an LDHA gene and an SLC7A5 gene. Reagents for detecting the expression levels of the SLC25A39 gene, the NME4 gene, the LDHA gene and the SLC7A5 gene in the biomarker combination can be applied to preparation of products for auxiliary diagnosis of the lung adenocarcinoma and risk early warning of the lung adenocarcinoma complicated with ischemic stroke, and the effect of one-detection dual-energy is achieved.

Application of STEAP3 in medicine for preventing, diagnosing and/or treating heart failure and medical inspection product

Resumen de: CN121818932A

The invention discloses application of functional protein STEAP3 in preparation of drugs for preventing, diagnosing and/or treating heart failure and medical inspection products, and belongs to the technical field of medicines. The invention discloses application of targeted regulation of STEAP3 in preparation of drugs for prevention, diagnosis and/or treatment of heart failure and medical inspection products. Experiments prove that targeted regulation of the protein can significantly improve the activity of cardiac muscle cells and enhance the ability of the protein to resist stress injury, and the protein also has the following five significant activities in DOX-induced heart failure model mouse in-vivo experiments: 1) improving cardiac dysfunction; the traditional Chinese medicine composition has the effects of clearing away heat and toxic materials, reversing myocardial tissue fibrosis, improving myocardial tissue sarcoma disorder, relieving myocardial cell apoptosis and reducing myocardial cell mitochondria damage.

PHARMACEUTICAL COMPOSITION CONTAINING CBFbeta-EXPRESSING VASCULAR SMOOTH MUSCLE CELLS OR CULTURE FLUID THEREOF AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF AGE-RELATED DISEASES

Resumen de: US20260097084A1

The present invention relates to a pharmaceutical composition containing Cbfβ (Core-binding factor subunit beta) expressing vascular smooth muscle cells or a culture fluid thereof as an active ingredient for the prevention or treatment of age-related diseases. It has been found that inhibition of Cbfβ expression in vascular smooth muscle cells promotes vascular calcification and osteoclast differentiation and that the culture fluid of Cbfβ-expressing vascular smooth muscle cells inhibits osteoclast differentiation. Thus, the composition can be advantageously utilized as a pharmaceutical composition for the prevention, treatment, alleviation, or diagnosis of age-related diseases.

METHODS AND SYSTEMS FOR RAPID DETECTION OF STROKE AND DETERMINATION OF ONSET VIA NEUROINFLAMMATION BIOMARKERS

Resumen de: US20260098869A1

Disclosed herein are methods, devices, and systems useful for identifying a subject having suffered a stroke and for identifying onset time of the stroke. In many embodiments, accurately determining a stroke and its onset allows for use of therapeutic drugs to alleviate symptoms that may not be available without these determinations. In many embodiments, the methods, devices, and systems are useful in identifying and analyzing IL-6 levels in the subject's blood. In some embodiments, the biomarker is detected using ELISA, SPR, molecular array, SiMoA, Ella, ECL.

Application of 4-VPS in preparation of kit for screening and/or diagnosing hypertensive kidney injury

Resumen de: CN121805570A

The invention relates to the technical field of biological medicine, in particular to application of 4-VPS in preparation of a kit for screening and/or diagnosing hypertensive kidney injury. According to the invention, a detection sample of 4-VPS is peripheral blood, and the sample is convenient to collect, minimally invasive and easy to popularize clinically; meanwhile, functional experiments prove that 4-VPS can directly induce kidney injury, early diagnosis of hypertensive nephropathy is achieved through 4-VPS, a patient can receive intervention treatment in the early stage of the disease, the disease is delayed or even prevented from developing into the end-stage nephropathy, the requirement of the patient for subsequent dialysis treatment or kidney transplantation is reduced, personal medical expenditure is reduced, and the treatment cost is reduced. Meanwhile, consumption of social medical resources is reduced, and remarkable economic benefits are achieved.

CFTSR gene, CFTSR gene simulant and application of CFTSR gene simulant

Resumen de: CN121801908A

The invention belongs to the technical field of biology, and particularly relates to a CFTSR gene, a CFTSR gene simulant and application of the CFTSR gene simulant. The nucleic acid sequence of the CFTSR gene is as shown in SEO ID NO. 1. The nucleic acid sequence of the CFTSR gene simulant is as shown in SEO ID NO. 2. The CFTSR gene provided by the invention can be used as a marker for fibroblast activation, and is used for a kit for detecting cardiac fibroblast activation. The CFTSR gene simulant can be used as a therapeutic drug for myocardial infarction injury, and the overexpression of the CFTSR gene can significantly inhibit the proliferation of fibroblasts and activate the repair of damaged myocardial tissues. Based on CFTSR mimics, a simulant of the CFTSR gene is constructed, and the simulant can be conveyed to the position of a heart lesion and can be used as a medicine for treating myocardial infarction injury, so that effective treatment of the lesion is realized.

Application of STAT1 inhibitor and detection preparation and construction method of vascular transplantation reconstruction model

Resumen de: CN121796597A

The invention discloses application of an STAT1 inhibitor and a detection preparation and a construction method of a vascular transplantation remodeling model, and belongs to the technical field of transplantation vascular remodeling treatment and diagnosis. The STAT1 is used as a target spot for preventing, treating and/or relieving the transplanted vascular remodeling and related diseases, meanwhile, the STAT1 is used as a biomarker for diagnosing the transplanted vascular remodeling, and a new thought is provided for preventing, treating and/or relieving the transplanted vascular remodeling and the related diseases.

Pharmaceutical application of RNA helicase DHX8

Resumen de: CN121802037A

The invention discloses pharmaceutical application of RNA helicase DHX8, including application of the RNA helicase DHX8 in aortic dissection diagnosis, treatment and drug development. It is found for the first time that DHX8 is significantly down-regulated in aortic dissection patients, animal models and vascular endothelial cells, and overexpression of DHX8 can effectively up-regulate endothelial cell tight connection related genes and repair the endothelial barrier function. The Si DHX8 is used for transfecting human umbilical vein endothelial cells (HUVECs), and the DHX8 is knocked down, so that the tight connection gene OCLN is obviously reduced; when the OE DHX8 plasmid is used for transfecting the HUVECs and overexpressing the DHX8, the tight connection genes OCLN, JAM-A, ZO-1 and VE-cadherin are found to be obviously up-regulated. The DHX8 is used as a new target for aortic dissection diagnosis and treatment, and a detection reagent, a gene therapy vector and an agonist drug of the DHX8 have important clinical transformation values.

YBX3 gene, YBX3 gene inhibitor and application of YBX3 gene inhibitor

Resumen de: CN121780679A

The invention belongs to the field of biological medicine, and particularly relates to a YBX3 gene, a YBX3 gene inhibitor and application of the YBX3 gene inhibitor. The invention discloses application of the YBX3 gene as a biomarker in preparation of a product for detecting cardiac fibrosis. The nucleotide sequence of the YBX3 gene is as shown in SEQ ID NO. 1. The invention discloses application of a YBX3 gene inhibitor in preparation of drugs for preventing and/or treating heart diseases. The YBX3 gene inhibitor is shRNA (short hairpin ribonucleic acid) and has a nucleotide sequence as shown in SEQ ID NO. 3. When myocardial infarction occurs, mRNA and protein level expression activity of the YBX3 gene is remarkably improved and is related to fibroblast activation, and the silent YBX3 gene can remarkably inhibit fibroblast activation. The existing myocardial infarction injury medicine has a limited treatment effect, so that the YBX3 can improve the clinical prognosis of myocardial infarction injury by regulating and controlling the activation of cell fibrosis.

Method, system and equipment for predicting sensitivity of patient with vascular remodeling lesion caused by circadian rhythm disorder to targeted IRF1 treatment

Resumen de: CN121789763A

The invention discloses a method, a system and equipment for predicting sensitivity of a patient with vascular remodeling lesion caused by circadian rhythm disorder to targeted IRF1 treatment. The invention discovers that circadian rhythm regulates inflammatory response of a body through IRF1 to cause vascular remodeling lesion for the first time, which prompts that a targeted IRF1 treatment method can be adopted for a patient with vascular remodeling caused by circadian rhythm disorder, so that a clinician is guided to formulate an individualized treatment scheme for the patient.

Methods for diagnosing predicting or monitoring myocardial infarction based on methylation biomarkers

Resumen de: KR20260045555A

본 발명은 메틸화 바이오마커를 기반 심근경색의 진단, 예측 또는 모니터링 방법에 관한 것으로, 심근경색 환자군에서 차별적으로 변화된 메틸화 수준을 나타내는 특정 메틸화 마커 및 유전자를 발굴하였으므로, 심근경색을 조기에 객관적으로 예측, 진단, 모니터링 및 예후를 평가하는데 유용하게 이용될 수 있다.

COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE

Resumen de: AU2026201866A1

Methods and compositions are provided for detecting a predisposition for cardiovascular disease in an individual. disease in an individual. ar a r d i s e a s e i n a n i n d i v i d u a l

Human venous thrombosis risk gene polymorphism detection primer probe composition as well as preparation and application thereof

Resumen de: CN121759597A

The invention provides a human venous thrombosis risk gene polymorphism detection primer probe composition as well as preparation and application thereof, and belongs to the technical field of nucleic acid detection methods. The primer probe composition comprises the following sequences: a primer pair PAI-1-F and PAI-1-R which are used for detecting the PAI-14G/5G site and are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2, and a probe PAI-1-P of which the sequence is shown as SEQ ID NO: 3; the probe is used for detecting PROCc.565Cgt; the primer pair of the T site PROC (565 Cgt; t)-F and PROC (565 Cgt; the invention relates to a kit for detecting the content of procyanidine, in particular to a kit for detecting the content of procyanidine, which comprises a probe PROC (565Cgt, T)-R and a probe PROC (565Cgt; t)-P, the sequence of which is as shown in SEQ ID NO: 6; the detection kit is used for detecting MTHFRc.677Cgt; the sequences of the primer pair MTHFR-F and MTHFR-R of the T site are respectively shown as SEQIDNO: 7 and SEQIDNO: 8, and the sequence of the probe MTHFR-P is shown as SEQIDNO: 9; wherein the 5'end of the probe is marked with a fluorophore, the 3 'end of the probe is marked with a quenching group, and the first three basic groups are modified by phosphoric acid. The kit is high in detection sensitivity.

Biomarker for treating post-stroke depression and application thereof

Resumen de: CN121759593A

The invention discloses a biomarker for treating post-stroke depression and application thereof, and belongs to the technical field of biomedicine. The biomarker is a micro ribonucleic acid-146 (miR-146) family member, and specifically comprises miR146b (micro ribonucleic acid)-3p, miR146a (micro ribonucleic acid)-5p, miR146a (micro ribonucleic acid)-3p and miR146b (micro ribonucleic acid)-5p. Experiments prove that the expression of miR146b-3p and miR146a-5p in hippocampal tissues of mice in a PSD state is up-regulated, the expression of miR146a-3p and miR146b-5p is down-regulated, and the expression of the subtypes can be regulated to a normal level by using radix bupleuri liver soothing powder (CSS). The biomarker can be used for PSD diagnosis, illness state evaluation and treatment effect monitoring, provides a target spot for screening and research and development of PSD treatment drugs, and has important clinical application value and scientific research significance.

Application of sFRP2 in preparation of medicine for treating ischemic heart failure by inhibiting Wnt/beta-catenin signal channel, related kit and medicine screening method

Nº publicación: CN121731470A 27/03/2026

Solicitante:

FIRST TEACHING HOSPITAL XINJIANG MEDICAL UNIV
\u65B0\u7586\u533B\u79D1\u5927\u5B66\u7B2C\u4E00\u9644\u5C5E\u533B\u9662

Resumen de: CN121731470A

The invention discloses application of sFRP2 in preparation of a medicine for treating ischemic heart failure by inhibiting a Wnt/beta-catenin signal channel, a related kit and a medicine screening method, relates to the technical field of biological medicines, and discloses application of sFRP2 in preparation of a medicine for treating heart failure caused by ischemic cardiomyopathy by inhibiting the Wnt/beta-catenin signal channel. The medicine comprises an effective dose of sFRP2 protein; the medicine is characterized by comprising a Wnt/beta-catenin signal channel inhibitor, the invention relates to a kit for evaluating the risk of ischemic heart failure. The kit comprises a reagent for detecting the expression level of sFRP2 and Wnt/beta-catenin; the invention relates to an application in a medicine for treating ischemic heart failure by inhibiting a Wnt/beta-catenin signal channel, a related kit and a medicine screening method, which are used for developing a new treatment medicine and improving the treatment effect of the ischemic heart failure. Meanwhile, the invention provides a kit for evaluating the risk of ischemic heart failure, and early and accurate diagnosis and risk evaluation of the disease are realized.